Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027

ワクチンアジュバントのグローバル市場予測(~2027):乳液、病原体成分、サポニンベース、微粒子、その他

◆タイトル:Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027
◆商品コード:BT4378-22
◆調査・発行会社:MarketsandMarkets
◆発行日:2022年8月31日
◆ページ数:206
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥0見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社の最新調査レポートによると、世界のワクチンアジュバント市場規模は、2022年15億ドルから2027年16億ドルまで年平均1.7%成長すると推定されます。当書は、ワクチンアジュバントの世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(乳液、病原体成分、サポニンベース、微粒子、その他)分析、投与経路別(皮下、筋肉内、その他)分析、疾患種類別(感染症、癌、その他)分析、用途別(研究、商業)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況、企業情報などについて総合的にまとめています。なお、当書に掲載されている企業情報には、GSK plc (UK)、Dynavax Technologies (US)、Novavax (US)、Agenus Inc. (US)、Croda International plc (UK)、Seppic (France)、OZ Biosciences (US)、Phibro Animal Health Corporation (US)、Associated British Foods plc (UK)、InvivoGen (US)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のワクチンアジュバント市場規模:製品別
- 乳液アジュバントの市場規模
- 病原体成分の市場規模
- サポニンベースアジュバントの市場規模
- 微粒子アジュバントの市場規模
- その他アジュバントの市場規模
・世界のワクチンアジュバント市場規模:投与経路別
- 皮下用ワクチンアジュバントの市場規模
- 筋肉内用ワクチンアジュバントの市場規模
- その他投与経路用ワクチンアジュバントの市場規模
・世界のワクチンアジュバント市場規模:疾患別
- 感染症用ワクチンアジュバントの市場規模
- 癌用ワクチンアジュバントの市場規模
- その他疾患用ワクチンアジュバントの市場規模
・世界のワクチンアジュバント市場規模:用途別
- 研究における市場規模
- 商業における市場規模
・世界のワクチンアジュバント市場規模:地域別
- 北米のワクチンアジュバント市場規模
- ヨーロッパのワクチンアジュバント市場規模
- アジア太平洋のワクチンアジュバント市場規模
- 中南米のワクチンアジュバント市場規模
- 中東・アフリカのワクチンアジュバント市場規模
・競争状況
・企業情報

“The vaccine adjuvants market is projected to reach USD 1.6 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 1.7% during the forecast period.”
The growth of the market is projected to be driven by factors such as the rising prevalence of infectious diseases, increasing number of COVID-19 vaccines in the development pipeline, and increasing focus on immunization programs.
The adjuvant emulsions accounted for the largest share of the product segment in the vaccine adjuvants market in 2021.
Adjuvant emulsions function by generating depots that can trap antigens at the injection site. This results in slow release to continue the stimulation of the immune system. The adjuvant emulsions segment accounted for the largest share of the market in 2021. The extensive use of adjuvant emulsions in COVID-19 and other infectious diseases and the rising prevalence of infectious diseases are driving the growth of the adjuvant emulsions segment during the forecast period.
The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2021.

“The infectious diseases segment accounted for the largest share of the market in 2021
The large share of this segment can be attributed to the increasing prevalence of infectious diseases and the rising demand for new adjuvanted vaccines.

Key players in the vaccine adjuvants market include Prominent players in the global vaccine adjuvants market are GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

“Asia Pacific: The fastest-growing region in the vaccine adjuvants market”
The Asia Pacific is estimated to be the fastest-growing segment of the market, owing to the increasing investments in the life sciences sector and rising awareness through conferences and symposiums. In this region, China and Japan are the largest markets while India is projected to grow at a highest CAGR during the forecast period.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:
• GSK plc (UK)
• Dynavax Technologies (US)
• Novavax (US)
• Agenus Inc. (US)
• Croda International plc (UK)
• Seppic (France)
• OZ Biosciences (US)
• Phibro Animal Health Corporation (US)
• Associated British Foods plc (UK)
• InvivoGen (US)
• Merck KGaA (Germany)
• CSL Limited (Australia)
• Vertellus (US)
• Allergy Therapeutics (UK)
• Riboxx GmbH (Germany)
• CaPtivatϵ Pharmaceuticals LLC (US)
• EuBiologics Co., Ltd. (South Korea)
• Pacific GeneTech Limited (US)
• Hawaii Biotech Inc. (US)
• Vaxine Pty Ltd. (Australia)
• Creative Diagnostics (US)
• LiteVax BV (Netherlands)
• Mukta Industries (India)
• Oncovir, Inc. (US)
• TiterMax USA, Inc. (US).

Research Coverage:
This report provides a detailed picture of the vaccine adjuvants market. It aims at estimating the size and future growth potential of the market across different segments such as the product, functionality, formulation and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccine adjuvants market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS AND EXCLUSIONS 31
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 YEARS CONSIDERED 32
1.4 CURRENCY 32
1.5 LIMITATIONS 32
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH APPROACH 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 PRIMARY RESEARCH 36
FIGURE 2 VACCINE ADJUVANTS MARKET: PRIMARY RESPONDENTS 36
2.2 MARKET ESTIMATION METHODOLOGY 37
FIGURE 3 VACCINE ADJUVANTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021 37
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 38
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 39
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 39
2.3 MARKET GROWTH RATE PROJECTIONS 40
FIGURE 6 VACCINE ADJUVANTS MARKET (DEMAND SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 41
2.4 DATA TRIANGULATION 42
FIGURE 7 DATA TRIANGULATION METHODOLOGY 42
2.5 RESEARCH ASSUMPTIONS 43
2.6 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
FIGURE 8 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 44
FIGURE 9 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2022 VS. 2027 (USD MILLION) 45
FIGURE 10 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2022 VS. 2027 (USD MILLION) 45
FIGURE 11 VACCINE ADJUVANTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 46
FIGURE 12 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2022 VS. 2027 (USD MILLION) 46
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF VACCINE ADJUVANTS MARKET 47
4 PREMIUM INSIGHTS 48
4.1 VACCINE ADJUVANTS MARKET OVERVIEW 48
FIGURE 14 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 48
4.2 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT AND COUNTRY (2021) 49
FIGURE 15 ADJUVANT EMULSIONS ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 49
4.3 VACCINE ADJUVANTS MARKET SHARE, BY PRODUCT, 2022 VS. 2027 50
FIGURE 16 ADJUVANT EMULSIONS SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027 50
4.4 VACCINE ADJUVANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 18 VACCINE ADJUVANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
TABLE 1 VACCINE ADJUVANTS MARKET: IMPACT ANALYSIS 52
5.2.1 DRIVERS 52
5.2.1.1 Rising prevalence of infectious diseases 52
5.2.1.2 Increasing use of adjuvants in vaccines 53
5.2.1.3 Collaborations and partnerships among market players for development of vaccine adjuvants 53
5.2.1.4 Increasing number of COVID-19 vaccines in development pipeline 53
FIGURE 19 TOP LOCATIONS BASED ON NUMBER OF COVID-19 VACCINES IN DEVELOPMENT PIPELINE (AS OF OCTOBER 2021) 54
5.2.1.5 Increasing focus on immunization programs 54
5.2.2 RESTRAINTS 54
5.2.2.1 Skepticism about animal-sourced vaccine adjuvants and limitations on shark fishing 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Rising funding for vaccines and infectious disease research activities 55
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION) 55
5.2.3.2 Development of plant-based vaccine adjuvants 55
5.2.4 CHALLENGES 56
5.2.4.1 Side effects and high toxicity of adjuvants 56
5.3 RANGES/SCENARIOS 56
FIGURE 20 SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF VACCINE ADJUVANTS MARKET 56
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 57
FIGURE 21 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VACCINE ADJUVANT PROVIDERS 57
5.5 PRICING ANALYSIS 57
5.5.1 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS 57
TABLE 3 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY MARKET PLAYERS 57
5.5.2 AVERAGE SELLING PRICE TREND 58
5.6 TECHNOLOGY ANALYSIS 58
5.6.1 SUPERCRITICAL FLUID EXTRACTION TECHNOLOGY 58
5.7 VALUE CHAIN ANALYSIS 59
FIGURE 22 VALUE CHAIN ANALYSIS 59
5.8 ECOSYSTEM ANALYSIS 60
FIGURE 23 ECOSYSTEM ANALYSIS 60
TABLE 4 SUPPLY CHAIN ECOSYSTEM 60
5.9 PATENT ANALYSIS 61
FIGURE 24 PATENT APPLICATIONS RELATED TO VACCINE ADJUVANTS MARKET, JANUARY 2012–AUGUST 2022 61
5.10 KEY CONFERENCES AND EVENTS IN 2022–2023 62
TABLE 5 LIST OF CONFERENCES AND EVENTS IN VACCINE ADJUVANTS MARKET 62
5.11 REGULATORY ANALYSIS 63
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS IN DIFFERENT REGIONS/COUNTRIES 63
5.12 PORTER’S FIVE FORCES ANALYSIS 64
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 64
5.12.1 THREAT OF NEW ENTRANTS 64
5.12.2 THREAT OF SUBSTITUTES 65
5.12.3 BARGAINING POWER OF BUYERS 65
5.12.4 BARGAINING POWER OF SUPPLIERS 65
5.12.5 DEGREE OF COMPETITION 65
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.13.1 KEY STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES AND THEIR INFLUENCE ON BUYING PROCESS 66
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ON BUYING PROCESS OF VACCINE ADJUVANTS 66
5.13.2 BUYING CRITERIA FOR VACCINE ADJUVANTS 66
FIGURE 26 BUYING CRITERIA FOR VACCINE ADJUVANTS 66
6 VACCINE ADJUVANTS MARKET, BY PRODUCT 67
6.1 INTRODUCTION 68
TABLE 7 VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 68
6.2 ADJUVANT EMULSIONS 68
6.2.1 ADJUVANT EMULSIONS FUNCTION BY GENERATING DEPOTS THAT TRAP ANTIGENS AT INJECTION SITE 68
TABLE 8 ADJUVANT EMULSIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 69
TABLE 9 NORTH AMERICA: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 69
TABLE 10 EUROPE: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 70
TABLE 11 ASIA PACIFIC: ADJUVANT EMULSIONS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 70
6.3 PATHOGEN COMPONENTS 70
6.3.1 PROMINENT MARKET PLAYERS DEVELOPING BACTERIA-DERIVED ADJUVANTS—KEY FACTOR SUPPORTING MARKET GROWTH 70
TABLE 12 PATHOGEN COMPONENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 71
TABLE 13 NORTH AMERICA: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 71
TABLE 14 EUROPE: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 72
TABLE 15 ASIA PACIFIC: PATHOGEN COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 72
6.4 SAPONIN-BASED ADJUVANTS 73
6.4.1 GROWING DEMAND FOR SAPONIN-BASED ADJUVANTS TO DRIVE MARKET 73
TABLE 16 SAPONIN-BASED ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 73
TABLE 17 NORTH AMERICA: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 18 EUROPE: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 19 ASIA PACIFIC: SAPONIN-BASED ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
6.5 PARTICULATE ADJUVANTS 75
6.5.1 MINERAL-BASED ADJUVANTS MOST WIDELY USED AMONG PARTICULATE ADJUVANTS 75
TABLE 20 PARTICULATE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 21 NORTH AMERICA: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
TABLE 22 EUROPE: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
TABLE 23 ASIA PACIFIC: PARTICULATE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
6.6 OTHER ADJUVANTS 77
TABLE 24 OTHER VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 77
TABLE 25 NORTH AMERICA: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 26 EUROPE: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 78
TABLE 27 ASIA PACIFIC: OTHER VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 78

7 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION 79
7.1 INTRODUCTION 80
TABLE 28 VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 80
7.2 INTRAMUSCULAR 80
7.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT 80
TABLE 29 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR ADMINISTRATION 81
TABLE 30 VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION) 81
TABLE 31 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 32 EUROPE: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 33 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INTRAMUSCULAR ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 82
7.3 SUBCUTANEOUS 83
7.3.1 ADVANTAGES OFFERED BY SUBCUTANEOUS ADMINISTRATION TO DRIVE MARKET 83
TABLE 34 ADVANTAGES AND DISADVANTAGES OF SUBCUTANEOUS ADMINISTRATION 83
TABLE 35 VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION) 83
TABLE 36 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 37 EUROPE: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 38 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 84
7.4 OTHER ROUTES OF ADMINISTRATION 85
TABLE 39 VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2020–2027 (USD MILLION) 85
TABLE 40 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 41 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION) 86
8 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE 87
8.1 INTRODUCTION 88
TABLE 43 VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 88
8.2 INFECTIOUS DISEASES 88
8.2.1 INCREASED PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 88
TABLE 44 VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 45 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 46 EUROPE: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 47 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 90
8.3 CANCER 91
8.3.1 INCREASING DEMAND FOR NOVEL CANCER VACCINES TO SUPPORT MARKET GROWTH 91
TABLE 48 VACCINE ADJUVANTS MARKET FOR CANCER, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 49 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 50 EUROPE: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 51 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.4 OTHER DISEASES 93
TABLE 52 VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY REGION,
2020–2027 (USD MILLION) 93
TABLE 53 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 54 EUROPE: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 55 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 94
9 VACCINE ADJUVANTS MARKET, BY APPLICATION 95
9.1 INTRODUCTION 96
TABLE 56 VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
9.2 RESEARCH APPLICATIONS 96
9.2.1 EXTENSIVE R&D FOR DEVELOPMENT OF VACCINE ADJUVANTS TO DRIVE MARKET 96
TABLE 57 VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 58 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 59 EUROPE: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 60 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
9.3 COMMERCIAL APPLICATIONS 98
9.3.1 GROWING USE OF VACCINE ADJUVANTS FOR COMMERCIAL APPLICATIONS TO SUPPORT MARKET GROWTH 98
TABLE 61 VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS,
BY REGION, 2020–2027 (USD MILLION) 99
TABLE 62 NORTH AMERICA: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 63 EUROPE: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 64 ASIA PACIFIC: VACCINE ADJUVANTS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 100
10 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY 101
10.1 INTRODUCTION 102
TABLE 65 VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 102
10.2 HUMAN VACCINE ADJUVANTS 102
10.2.1 INCREASE IN PARTNERSHIPS FOR DEVELOPMENT OF HUMAN VACCINE ADJUVANTS 102
TABLE 66 HUMAN VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 103
TABLE 67 NORTH AMERICA: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 68 EUROPE: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 103
TABLE 69 ASIA PACIFIC: HUMAN VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 104
10.3 VETERINARY VACCINE ADJUVANTS 104
10.3.1 DEVELOPMENT OF ANIMAL VACCINES GOVERNED BY FEWER REGULATORY ASPECTS 104
TABLE 70 VETERINARY VACCINE ADJUVANTS MARKET, BY REGION,
2020–2027 (USD MILLION) 105
TABLE 71 NORTH AMERICA: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 72 EUROPE: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 73 ASIA PACIFIC: VETERINARY VACCINE ADJUVANTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 106
11 VACCINE ADJUVANTS MARKET, BY REGION 107
11.1 INTRODUCTION 108
TABLE 74 VACCINE ADJUVANTS MARKET, BY REGION, 2020–2027 (USD MILLION) 108
11.2 NORTH AMERICA 108
FIGURE 27 NORTH AMERICA: VACCINE ADJUVANTS MARKET SNAPSHOT 109
TABLE 75 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 110
TABLE 76 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 110
TABLE 77 NORTH AMERICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 110
TABLE 78 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 111
TABLE 79 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 111
TABLE 80 NORTH AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 111

11.2.1 US 112
11.2.1.1 US dominates North American vaccine adjuvants market 112
TABLE 81 US: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 113
TABLE 82 US: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 113
TABLE 83 US: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 113
TABLE 84 US: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 114
TABLE 85 US: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 114
11.2.2 CANADA 114
11.2.2.1 Increasing government funding for vaccine research to drive market 114
TABLE 86 CANADA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 115
TABLE 87 CANADA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 115
TABLE 88 CANADA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 115
TABLE 89 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 116
TABLE 90 CANADA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 116
11.3 EUROPE 117
TABLE 91 EUROPE: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 117
TABLE 92 EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 117
TABLE 93 EUROPE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 118
TABLE 94 EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 118
TABLE 95 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 118
TABLE 96 EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 119
11.3.1 GERMANY 119
11.3.1.1 Growing funding from government organizations to drive market 119
TABLE 97 GERMANY: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 120
TABLE 98 GERMANY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 120
TABLE 99 GERMANY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 120
TABLE 100 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 121
TABLE 101 GERMANY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 121
11.3.2 UK 121
11.3.2.1 Rising investments in vaccine development to boost market growth 121
TABLE 102 UK: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 122
TABLE 103 UK: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 122
TABLE 104 UK: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 123
TABLE 105 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 123
TABLE 106 UK: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 123
11.3.3 FRANCE 124
11.3.3.1 Focus on new vaccine development to drive market 124
TABLE 107 FRANCE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 124
TABLE 108 FRANCE: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 125
TABLE 109 FRANCE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 125
TABLE 110 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 125
TABLE 111 FRANCE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 126
11.3.4 ITALY 126
11.3.4.1 Increase in R&D for vaccines and government initiatives—key factors driving market 126
TABLE 112 ITALY: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 126
TABLE 113 ITALY: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION,
2020–2027 (USD MILLION) 127
TABLE 114 ITALY: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 127
TABLE 115 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 127
TABLE 116 ITALY: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 128
11.3.5 SPAIN 128
11.3.5.1 Increasing investments in vaccine development by government and private organizations to drive market 128
TABLE 117 SPAIN: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 129
TABLE 118 SPAIN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 129
TABLE 119 SPAIN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 129
TABLE 120 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 130
TABLE 121 SPAIN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 130
11.3.6 REST OF EUROPE 130
TABLE 122 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 131
TABLE 123 REST OF EUROPE: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 131
TABLE 124 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 131
TABLE 125 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 132
TABLE 126 REST OF EUROPE: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 132
11.4 ASIA PACIFIC 132
FIGURE 28 ASIA PACIFIC: VACCINE ADJUVANTS MARKET SNAPSHOT 133
TABLE 127 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 134
TABLE 128 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 134
TABLE 129 ASIA PACIFIC: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 134
TABLE 130 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 135
TABLE 131 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 132 ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 135
11.4.1 CHINA 136
11.4.1.1 Government support and strategic initiatives by key players to strengthen biotechnology sector 136
TABLE 133 CHINA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 136
TABLE 134 CHINA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 137
TABLE 135 CHINA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 137
TABLE 136 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 137
TABLE 137 CHINA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 138
11.4.2 JAPAN 138
11.4.2.1 Government initiatives for vaccines to boost market 138
TABLE 138 JAPAN: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 138
TABLE 139 JAPAN: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 139
TABLE 140 JAPAN: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 139
TABLE 141 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 139
TABLE 142 JAPAN: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 140
11.4.3 INDIA 140
11.4.3.1 Growth of the biotechnology sector and development of new vaccines to drive market 140
TABLE 143 INDIA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 140
TABLE 144 INDIA: VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 141
TABLE 145 INDIA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 141
TABLE 146 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 141
TABLE 147 INDIA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY,
2020–2027 (USD MILLION) 142
11.4.4 REST OF ASIA PACIFIC 142
TABLE 148 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 142
TABLE 149 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 143
TABLE 150 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 143
TABLE 151 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 152 REST OF ASIA PACIFIC: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 144
11.5 LATIN AMERICA 144
11.5.1 SURGE IN PHARMACEUTICAL AND BIOTECHNOLOGY RESEARCH—
KEY FACTOR DRIVING MARKET 144
TABLE 153 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 144
TABLE 154 LATIN AMERICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 145
TABLE 155 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 145
TABLE 156 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 145
TABLE 157 LATIN AMERICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 146
11.6 MIDDLE EAST AND AFRICA 146
11.6.1 INCREASING FUNDING AND GRANTS FOR VACCINE DEVELOPMENT TO DRIVE MARKET 146
TABLE 158 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 146
TABLE 159 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET,
BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 147
TABLE 160 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 147
TABLE 161 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 147
TABLE 162 MIDDLE EAST AND AFRICA: VACCINE ADJUVANTS MARKET, BY APPLICATION CATEGORY, 2020–2027 (USD MILLION) 148
12 COMPETITIVE LANDSCAPE 149
12.1 INTRODUCTION 149
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 150
FIGURE 29 VACCINE ADJUVANTS MARKET: STRATEGIES ADOPTED 150
12.3 MARKET SHARE ANALYSIS 151
FIGURE 30 VACCINE ADJUVANTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 151
TABLE 163 VACCINE ADJUVANTS MARKET: DEGREE OF COMPETITION 151
12.4 REVENUE ANALYSIS 152
FIGURE 31 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 152
12.5 COMPANY EVALUATION QUADRANT 153
12.5.1 STARS 153
12.5.2 EMERGING LEADERS 153
12.5.3 PERVASIVE PLAYERS 153
12.5.4 PARTICIPANTS 153
FIGURE 32 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX, 2021 154
12.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 155
12.6.1 COMPANY FOOTPRINT (25 COMPANIES) 155
TABLE 164 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 155
12.6.2 COMPANY PRODUCT FOOTPRINT (25 COMPANIES) 156
TABLE 165 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 156
12.6.3 COMPANY REGIONAL FOOTPRINT (25 COMPANIES) 157
TABLE 166 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VACCINE ADJUVANTS MARKET 157
12.7 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 158
12.7.1 PROGRESSIVE COMPANIES 158
12.7.2 STARTING BLOCKS 158
12.7.3 RESPONSIVE COMPANIES 158
12.7.4 DYNAMIC COMPANIES 158
FIGURE 33 VACCINE ADJUVANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2021 159
12.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 160
TABLE 167 DETAILED LIST OF KEY STARTUP/SMES 160
TABLE 168 COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES) 161
12.9 COMPETITIVE SCENARIO AND TRENDS 161
12.9.1 PRODUCT LAUNCHES 161
TABLE 169 KEY PRODUCT LAUNCHES, JANUARY 2019–JULY 2022 161
12.9.2 DEALS 162
TABLE 170 KEY DEALS, JANUARY 2019–JULY 2022 162
12.9.3 OTHER KEY DEVELOPMENTS 163
TABLE 171 OTHER KEY DEVELOPMENTS, JANUARY 2019–JULY 2022 163
13 COMPANY PROFILES 164
13.1 KEY PLAYERS 164
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 GSK PLC 164
TABLE 172 GSK PLC: BUSINESS OVERVIEW 164
FIGURE 34 GSK PLC: COMPANY SNAPSHOT (2021) 165
13.1.2 DYNAVAX TECHNOLOGIES 169
TABLE 173 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW 169
FIGURE 35 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT (2021) 169
13.1.3 NOVAVAX 173
TABLE 174 NOVAVAX: BUSINESS OVERVIEW 173
FIGURE 36 NOVAVAX: COMPANY SNAPSHOT (2021) 173
13.1.4 AGENUS INC. 176
TABLE 175 AGENUS INC.: BUSINESS OVERVIEW 176
FIGURE 37 AGENUS INC.: COMPANY SNAPSHOT (2021) 176
13.1.5 CRODA INTERNATIONAL PLC 178
TABLE 176 CRODA INTERNATIONAL PLC: BUSINESS OVERVIEW 178
FIGURE 38 CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT (2021) 179
13.1.6 SEPPIC (SUBSIDIARY OF AIR LIQUIDE GROUP) 181
TABLE 177 AIR LIQUIDE GROUP: BUSINESS OVERVIEW 181
FIGURE 39 AIR LIQUIDE: COMPANY SNAPSHOT (2021) 182
13.1.7 PHIBRO ANIMAL HEALTH CORPORATION 184
TABLE 178 PHIBRO ANIMAL HEALTH CORPORATION: BUSINESS OVERVIEW 184
FIGURE 40 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT (2020) 185
13.1.8 SPI PHARMA (SUBSIDIARY OF ASSOCIATED BRITISH FOODS PLC) 186
TABLE 179 ASSOCIATED BRITISH FOODS PLC: BUSINESS OVERVIEW 186
FIGURE 41 ASSOCIATED BRITISH FOODS PLC: COMPANY SNAPSHOT (2021) 187
13.1.9 CSL LIMITED 188
TABLE 180 CSL LIMITED: BUSINESS OVERVIEW 188
FIGURE 42 CSL LIMITED: COMPANY SNAPSHOT (2021) 189
13.1.10 MERCK KGAA 191
TABLE 181 MERCK KGAA: BUSINESS OVERVIEW 191
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT (2021) 192
13.1.11 OZ BIOSCIENCES 193
TABLE 182 OZ BIOSCIENCES: BUSINESS OVERVIEW 193
13.1.12 INVIVOGEN 194
TABLE 183 INVIVOGEN: BUSINESS OVERVIEW 194
13.1.13 ALLERGY THERAPEUTICS 196
TABLE 184 ALLERGY THERAPEUTICS: BUSINESS OVERVIEW 196
FIGURE 44 ALLERGY THERAPEUTICS: COMPANY SNAPSHOT (2020) 196
13.1.14 VERTELLUS 198
TABLE 185 VERTELLUS: BUSINESS OVERVIEW 198
13.1.15 EUBIOLOGICS CO., LTD. 199
TABLE 186 EUBIOLOGICS CO., LTD.: BUSINESS OVERVIEW 199
13.1.16 PACIFIC GENETECH LIMITED 200
TABLE 187 PACIFIC GENETECH LIMITED: BUSINESS OVERVIEW 200
13.1.17 HAWAII BIOTECH INC. 201
TABLE 188 HAWAII BIOTECH INC.: BUSINESS OVERVIEW 201
13.1.18 RIBOXX GMBH 202
TABLE 189 RIBOXX GMBH: BUSINESS OVERVIEW 202
13.1.19 CAPTIVATE PHARMACEUTICALS LLC 203
TABLE 190 CAPTIVATE PHARMACEUTICALS LLC: BUSINESS OVERVIEW 203
13.1.20 VAXINE PTY LTD. 204
TABLE 191 VAXINE PTY LTD.: BUSINESS OVERVIEW 204
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER COMPANIES 205
13.2.1 CREATIVE DIAGNOSTICS 205
13.2.2 LITEVAX BV 205
13.2.3 MUKTA INDUSTRIES 206
13.2.4 ONCOVIR, INC. 206
13.2.5 TITERMAX USA, INC. 207
14 APPENDIX 208
14.1 DISCUSSION GUIDE 208
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 211
14.3 CUSTOMIZATION OPTIONS 213
14.4 RELATED REPORTS 213
14.5 AUTHOR DETAILS 214



★調査レポート[ワクチンアジュバントのグローバル市場予測(~2027):乳液、病原体成分、サポニンベース、微粒子、その他] ( Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027 / BT4378-22) 販売に関する免責事項
[ワクチンアジュバントのグローバル市場予測(~2027):乳液、病原体成分、サポニンベース、微粒子、その他] ( Vaccine Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Global Forecast to 2027 / BT4378-22) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆